Condition: Healthy Volunteers · Sponsor: Climb Bio, Inc.
This Phase 1, first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CLYM116 in healthy volunteers.
This description comes directly from the study's public registry record.
Climb Bio Study Director · +1 866 857 2596 · clinicaltrials@climbbio.com
Always discuss trial participation with your own doctor first.
| Nucleus Network Brisbane | Brisbane, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07248865